Announced Date: 2025-06-03 (June 3, 2025)
Asset Name: ITG-1052 (Lenamilast)
Licensor: Suzhou Intragrand Pharma (China)
Licensee (Buyer): Transpire Bio Inc.（US）
.
Asset Modality: Small Molecule, inhaled
Asset Target: PDE4 inhibitor
Potential Indication: idiopathic pulmonary fibrosis and other indications
Current Stage: Preclinical
.
Scope of Authority:
Intragrand has granted Transpire Bio an exclusive license to develop, manufacture, and commercialize ITG-1052 in all territories except China.
.
Payment Detail:
Terms of the agreement are not disclosed.
.
Link:
